Please login to the form below

Not currently logged in
Email:
Password:

Asian patient groups give pharma above average marks for reputation

PatientView survey finds 49% believe sector has a good corporate reputation

PatientViewAsian patient groups have an above average impression of pharmaceutical companies, according to a new report.

New data from PatientView’s established corporate reputation survey show 49% of patient groups in Asia believe the sector has an ‘excellent’ or ‘good’ corporate reputation.

The figures, drawn from 98 patient groups from Australasia, Central Asia, East Asia, South Asia and South-East Asia, present a rosier picture than their counterparts from around the world, 37% of which held the same view.

PatientView’s 2016 Corporate Reputation of Pharma Companies survey covers the efforts of 16 global pharma companies including Pfizer - which was ranked the most familiar to the Asian patient groups.

Respondents also ranked AbbVie as overall first for corporate reputation among the groups familiar with the firm. The US company ranked first for patient-centricity, transparency and patient-group relations as well.

Meanwhile, GSK was placed first for the provision of ‘high-quality’ patient information and Novo Nordisk took first position for patient safety, high quality products and integrity.

Article by
Gemma Jones

16th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics